首页 > 最新文献

Current Infectious Disease Reports最新文献

英文 中文
Racial/Ethnic Inequities in Healthcare-associated Infections Under the Shadow of Structural Racism: Narrative Review and Call to Action. 在结构性种族主义的阴影下,医疗保健相关感染中的种族/民族不平等:叙述审查和行动呼吁。
IF 3.1 4区 医学 Q1 Medicine Pub Date : 2021-01-01 Epub Date: 2021-08-27 DOI: 10.1007/s11908-021-00758-x
Jiabi Chen, Rohan Khazanchi, Gonzalo Bearman, Jasmine R Marcelin

Purpose of review: The purpose of this study is to review racial and ethnic inequities in the incidence and prevention of healthcare-associated infections (HAIs) in the USA, identify gaps in the literature, and recommend future directions to mitigate these inequities.

Recent findings: While some existing literature has identified the presence of racial/ethnic inequities in HAI incidence and outcomes, few studies to date have evaluated whether HAI prevention efforts have mitigated these inequities. Factors contributing to inequities in HAI prevention may include unconscious bias of healthcare professionals towards minoritized patients; socioeconomic and structural inequities disparately affecting minoritized communities; the racial segregation of quality healthcare through hospital price discrimination; divergent reimbursement rates between public and private insurers; policies or performance metrics which underfund and financially penalize safety-net hospitals; and insufficient research evaluating and addressing HAI inequities.

Summary: Expansion of the literature is needed to further interrogate root causes and evaluate the impact of interventions on racial/ethnic inequities in HAI incidence. Measures to mitigate inequities might include teaching healthcare workers how to recognize and mitigate unconscious biases, expanding community resources which address the social and structural determinants of health, increasing access to preventive health services, reforming federal and institutional policies to better support safety-net hospitals and disincentivize price discrimination, and improving diversity and inclusion within the health workforce.

回顾目的:本研究的目的是回顾美国在医疗保健相关感染(HAIs)的发生率和预防方面的种族和民族不平等,找出文献中的差距,并建议未来的方向来减轻这些不平等。最近的发现:虽然一些现有文献已经确定了HAI发病率和结果中存在种族/民族不平等,但迄今为止很少有研究评估HAI预防工作是否减轻了这些不平等。导致HAI预防不公平的因素可能包括卫生保健专业人员对少数群体患者的无意识偏见;社会经济和结构不平等对少数群体社区的影响不同;医院价格歧视对优质医疗的种族隔离公共保险公司与私营保险公司报销比例的差异;使安全网医院资金不足和受到财政惩罚的政策或绩效指标;评估和解决HAI不平等的研究不足。总结:需要扩大文献来进一步询问根本原因并评估干预措施对HAI发病率中种族/民族不平等的影响。减轻不公平现象的措施可包括:教育保健工作者如何认识和减轻无意识的偏见,扩大社区资源以解决健康的社会和结构决定因素,增加获得预防性保健服务的机会,改革联邦和机构政策以更好地支持安全网医院和抑制价格歧视,以及改善保健工作人员的多样性和包容性。
{"title":"Racial/Ethnic Inequities in Healthcare-associated Infections Under the Shadow of Structural Racism: Narrative Review and Call to Action.","authors":"Jiabi Chen,&nbsp;Rohan Khazanchi,&nbsp;Gonzalo Bearman,&nbsp;Jasmine R Marcelin","doi":"10.1007/s11908-021-00758-x","DOIUrl":"https://doi.org/10.1007/s11908-021-00758-x","url":null,"abstract":"<p><strong>Purpose of review: </strong>The purpose of this study is to review racial and ethnic inequities in the incidence and prevention of healthcare-associated infections (HAIs) in the USA, identify gaps in the literature, and recommend future directions to mitigate these inequities.</p><p><strong>Recent findings: </strong>While some existing literature has identified the presence of racial/ethnic inequities in HAI incidence and outcomes, few studies to date have evaluated whether HAI prevention efforts have mitigated these inequities. Factors contributing to inequities in HAI prevention may include unconscious bias of healthcare professionals towards minoritized patients; socioeconomic and structural inequities disparately affecting minoritized communities; the racial segregation of quality healthcare through hospital price discrimination; divergent reimbursement rates between public and private insurers; policies or performance metrics which underfund and financially penalize safety-net hospitals; and insufficient research evaluating and addressing HAI inequities.</p><p><strong>Summary: </strong>Expansion of the literature is needed to further interrogate root causes and evaluate the impact of interventions on racial/ethnic inequities in HAI incidence. Measures to mitigate inequities might include teaching healthcare workers how to recognize and mitigate unconscious biases, expanding community resources which address the social and structural determinants of health, increasing access to preventive health services, reforming federal and institutional policies to better support safety-net hospitals and disincentivize price discrimination, and improving diversity and inclusion within the health workforce.</p>","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11908-021-00758-x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39388320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Diagnostic Challenges in Sepsis. 败血症的诊断挑战。
IF 3.1 4区 医学 Q1 Medicine Pub Date : 2021-01-01 Epub Date: 2021-10-25 DOI: 10.1007/s11908-021-00765-y
Chris F Duncan, Taryn Youngstein, Marianne D Kirrane, Dagan O Lonsdale

Purpose of review: Sepsis is a leading cause of death worldwide. Groundbreaking international collaborative efforts have culminated in the widely accepted surviving sepsis guidelines, with iterative improvements in management strategies and definitions providing important advances in care for patients. Key to the diagnosis of sepsis is identification of infection, and whilst the diagnostic criteria for sepsis is now clear, the diagnosis of infection remains a challenge and there is often discordance between clinician assessments for infection.

Recent findings: We review the utility of common biochemical, microbiological and radiological tools employed by clinicians to diagnose infection and explore the difficulty of making a diagnosis of infection in severe inflammatory states through illustrative case reports. Finally, we discuss some of the novel and emerging approaches in diagnosis of infection and sepsis.

Summary: While prompt diagnosis and treatment of sepsis is essential to improve outcomes in sepsis, there remains no single tool to reliably identify or exclude infection. This contributes to unnecessary antimicrobial use that is harmful to individuals and populations. There is therefore a pressing need for novel solutions. Machine learning approaches using multiple diagnostic and clinical inputs may offer a potential solution but as yet these approaches remain experimental.

综述目的:脓毒症是世界范围内死亡的主要原因。突破性的国际合作努力最终形成了被广泛接受的脓毒症生存指南,管理策略和定义的不断改进为患者护理提供了重要进展。脓毒症诊断的关键是感染的识别,虽然脓毒症的诊断标准现在很明确,但感染的诊断仍然是一个挑战,临床医生对感染的评估经常存在不一致。最近的发现:我们回顾了临床医生用于诊断感染的常用生化、微生物学和放射学工具的实用性,并通过说明性病例报告探讨了在严重炎症状态下诊断感染的困难。最后,我们讨论了一些新的和新兴的方法在诊断感染和败血症。摘要:虽然及时诊断和治疗脓毒症对于改善脓毒症的预后至关重要,但目前还没有一种工具可以可靠地识别或排除感染。这导致不必要的抗微生物药物使用,对个人和人群有害。因此,迫切需要新的解决方案。使用多种诊断和临床输入的机器学习方法可能提供一个潜在的解决方案,但目前这些方法仍处于实验阶段。
{"title":"Diagnostic Challenges in Sepsis.","authors":"Chris F Duncan,&nbsp;Taryn Youngstein,&nbsp;Marianne D Kirrane,&nbsp;Dagan O Lonsdale","doi":"10.1007/s11908-021-00765-y","DOIUrl":"https://doi.org/10.1007/s11908-021-00765-y","url":null,"abstract":"<p><strong>Purpose of review: </strong>Sepsis is a leading cause of death worldwide. Groundbreaking international collaborative efforts have culminated in the widely accepted surviving sepsis guidelines, with iterative improvements in management strategies and definitions providing important advances in care for patients. Key to the diagnosis of sepsis is identification of infection, and whilst the diagnostic criteria for sepsis is now clear, the diagnosis of infection remains a challenge and there is often discordance between clinician assessments for infection.</p><p><strong>Recent findings: </strong>We review the utility of common biochemical, microbiological and radiological tools employed by clinicians to diagnose infection and explore the difficulty of making a diagnosis of infection in severe inflammatory states through illustrative case reports. Finally, we discuss some of the novel and emerging approaches in diagnosis of infection and sepsis.</p><p><strong>Summary: </strong>While prompt diagnosis and treatment of sepsis is essential to improve outcomes in sepsis, there remains no single tool to reliably identify or exclude infection. This contributes to unnecessary antimicrobial use that is harmful to individuals and populations. There is therefore a pressing need for novel solutions. Machine learning approaches using multiple diagnostic and clinical inputs may offer a potential solution but as yet these approaches remain experimental.</p>","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8544629/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39578812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 16
Infection Prevention and Antimicrobial Stewardship Program Collaboration During the COVID-19 Pandemic: a Window of Opportunity. COVID-19 大流行期间的感染预防和抗菌药物管理计划合作:机会之窗。
IF 3.1 4区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2021-01-01 Epub Date: 2021-08-18 DOI: 10.1007/s11908-021-00759-w
Mariam Assi, Salma Abbas, Priya Nori, Michelle Doll, Emily Godbout, Gonzalo Bearman, Michael P Stevens

Purpose of review: We describe the similarities between antimicrobial stewardship programs (ASPs) and infection prevention programs (IPPs), and we discuss how these similarities lend themselves to synergy between programs. We also discuss how the COVID-19 pandemic has generated further opportunities for future collaborations that could benefit both programs.

Recent findings: The COVID-19 pandemic has created new needs, such as real-time data and access to personnel important to both programs, such as information technologists and infectious diseases specialists. It has also increased concerns about rising rates of antimicrobial resistance and healthcare-associated infections, both of which overlap significantly and are key focus areas for both ASPs and IPPs. These emergent issues have highlighted the need for enhanced program infrastructure and new team models. The shift towards telecommunication and telework has facilitated the creation of enhanced infrastructures for collaboration on activities ranging from data access and reporting to providing telehealth services to remote hospitals. These enhanced infrastructures can be leveraged in future collaborative efforts between ASPs and IPPs.

Summary: Collaboration between IPPs and ASPs can mitigate setbacks experienced by health systems during the current pandemic, enhance the performance of both programs in the post-pandemic era and increase their preparedness for future pandemic threats. As health systems plan for the post-pandemic era, they should invest in opportunities for synergy between ASPs and IPPs highlighted during the pandemic.

综述目的:我们描述了抗菌药物管理计划(ASP)和感染预防计划(IPP)之间的相似之处,并讨论了这些相似之处如何使计划之间产生协同效应。我们还讨论了 COVID-19 大流行如何为未来的合作创造了更多机会,从而使这两个计划受益:COVID-19 大流行带来了新的需求,如实时数据和对两个项目都很重要的人员(如信息技术专家和传染病专家)的访问。它还增加了对抗菌药耐药性和医疗相关感染率上升的担忧,这两个问题严重重叠,是 ASP 和 IPP 的重点关注领域。这些新出现的问题凸显了加强计划基础设施和新团队模式的必要性。向远程通信和远程工作的转变促进了从数据访问和报告到向偏远医院提供远程保健服务等活动的协作基础设施的增强。小结:IPP 和 ASP 之间的合作可以减轻卫生系统在当前大流行病期间所经历的挫折,提高这两个计划在大流行病后时期的绩效,并增强其应对未来大流行病威胁的准备。在卫生系统为后大流行时代制定计划时,它们应投资于在大流行期间突出强调的联系学校项目和综合方案之间协同作用的机会。
{"title":"Infection Prevention and Antimicrobial Stewardship Program Collaboration During the COVID-19 Pandemic: a Window of Opportunity.","authors":"Mariam Assi, Salma Abbas, Priya Nori, Michelle Doll, Emily Godbout, Gonzalo Bearman, Michael P Stevens","doi":"10.1007/s11908-021-00759-w","DOIUrl":"10.1007/s11908-021-00759-w","url":null,"abstract":"<p><strong>Purpose of review: </strong>We describe the similarities between antimicrobial stewardship programs (ASPs) and infection prevention programs (IPPs), and we discuss how these similarities lend themselves to synergy between programs. We also discuss how the COVID-19 pandemic has generated further opportunities for future collaborations that could benefit both programs.</p><p><strong>Recent findings: </strong>The COVID-19 pandemic has created new needs, such as real-time data and access to personnel important to both programs, such as information technologists and infectious diseases specialists. It has also increased concerns about rising rates of antimicrobial resistance and healthcare-associated infections, both of which overlap significantly and are key focus areas for both ASPs and IPPs. These emergent issues have highlighted the need for enhanced program infrastructure and new team models. The shift towards telecommunication and telework has facilitated the creation of enhanced infrastructures for collaboration on activities ranging from data access and reporting to providing telehealth services to remote hospitals. These enhanced infrastructures can be leveraged in future collaborative efforts between ASPs and IPPs.</p><p><strong>Summary: </strong>Collaboration between IPPs and ASPs can mitigate setbacks experienced by health systems during the current pandemic, enhance the performance of both programs in the post-pandemic era and increase their preparedness for future pandemic threats. As health systems plan for the post-pandemic era, they should invest in opportunities for synergy between ASPs and IPPs highlighted during the pandemic.</p>","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374122/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39338892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What Is the Impact of Lockdowns on Dengue? 封锁对登革热有什么影响?
IF 3.1 4区 医学 Q1 Medicine Pub Date : 2021-01-01 DOI: 10.1007/s11908-020-00744-9
Oliver Brady, Annelies Wilder-Smith

Purpose of review: Societal lockdowns in response to the COVID-19 pandemic have led to unprecedented disruption to daily life across the globe. A collateral effect of these lockdowns may be a change to transmission dynamics of a wide range of infectious diseases that are all highly dependent on rates of contact between humans. With timing, duration and intensity of lockdowns varying country-to-country, the wave of lockdowns in 2020 present a unique opportunity to observe how changes in human contact rates, disease control and surveillance affect dengue virus transmission in a global natural experiment. We explore the theoretical basis for the impact of lockdowns on dengue transmission and surveillance then summarise the current evidence base from country reports.

Recent findings: We find considerable variation in the intensity of dengue epidemics reported so far in 2020 with some countries experiencing historic low levels of transmission while others are seeing record outbreaks. Despite many studies warning of the risks of lockdown for dengue transmission, few empirically quantify the impact and issues such as the specific timing of the lockdowns and multi-annual cycles of dengue are not accounted for. In the few studies where such issues have been accounted for, the impact of lockdowns on dengue appears to be limited.

Summary: Studying the impact of lockdowns on dengue transmission is important both in how we deal with the immediate COVID-19 and dengue crisis, but also over the coming years in the post-pandemic recovery period. It is clear lockdowns have had very different impacts in different settings. Further analyses might ultimately allow this unique natural experiment to provide insights into how to better control dengue that will ultimately lead to better long-term control.

审查目的:为应对COVID-19大流行而实施的社会封锁,给全球日常生活带来了前所未有的中断。这些封锁的附带影响可能是一系列传染病的传播动态发生变化,这些传染病都高度依赖于人与人之间的接触率。由于各国封锁的时间、持续时间和强度各不相同,2020年的封锁浪潮提供了一个独特的机会,可以在全球自然实验中观察人类接触率、疾病控制和监测方面的变化如何影响登革热病毒传播。我们探讨了封锁对登革热传播和监测影响的理论基础,然后总结了目前来自国家报告的证据基础。最近的发现:我们发现,到目前为止,2020年报告的登革热流行强度差异很大,一些国家的传播水平处于历史低位,而另一些国家则出现了创纪录的疫情。尽管许多研究警告了封锁对登革热传播的风险,但很少有实证量化其影响,并且没有考虑到封锁的具体时间和登革热的多年周期等问题。在少数考虑到这些问题的研究中,封锁对登革热的影响似乎有限。总结:研究封锁对登革热传播的影响,不仅对我们如何应对当前的COVID-19和登革热危机很重要,而且对未来几年大流行后的恢复期也很重要。很明显,封锁在不同的环境中产生了非常不同的影响。进一步的分析可能最终使这一独特的自然实验为如何更好地控制登革热提供见解,从而最终实现更好的长期控制。
{"title":"What Is the Impact of Lockdowns on Dengue?","authors":"Oliver Brady,&nbsp;Annelies Wilder-Smith","doi":"10.1007/s11908-020-00744-9","DOIUrl":"https://doi.org/10.1007/s11908-020-00744-9","url":null,"abstract":"<p><strong>Purpose of review: </strong>Societal lockdowns in response to the COVID-19 pandemic have led to unprecedented disruption to daily life across the globe. A collateral effect of these lockdowns may be a change to transmission dynamics of a wide range of infectious diseases that are all highly dependent on rates of contact between humans. With timing, duration and intensity of lockdowns varying country-to-country, the wave of lockdowns in 2020 present a unique opportunity to observe how changes in human contact rates, disease control and surveillance affect dengue virus transmission in a global natural experiment. We explore the theoretical basis for the impact of lockdowns on dengue transmission and surveillance then summarise the current evidence base from country reports.</p><p><strong>Recent findings: </strong>We find considerable variation in the intensity of dengue epidemics reported so far in 2020 with some countries experiencing historic low levels of transmission while others are seeing record outbreaks. Despite many studies warning of the risks of lockdown for dengue transmission, few empirically quantify the impact and issues such as the specific timing of the lockdowns and multi-annual cycles of dengue are not accounted for. In the few studies where such issues have been accounted for, the impact of lockdowns on dengue appears to be limited.</p><p><strong>Summary: </strong>Studying the impact of lockdowns on dengue transmission is important both in how we deal with the immediate COVID-19 and dengue crisis, but also over the coming years in the post-pandemic recovery period. It is clear lockdowns have had very different impacts in different settings. Further analyses might ultimately allow this unique natural experiment to provide insights into how to better control dengue that will ultimately lead to better long-term control.</p>","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11908-020-00744-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9301684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 36
Reducing Central Line Associated Bloodstream Infections (CLABSIs) by Reducing Central Line Days. 通过减少中心静脉注射天数减少中心静脉相关血流感染(CLABSIs)。
IF 3.1 4区 医学 Q1 Medicine Pub Date : 2021-01-01 Epub Date: 2021-11-02 DOI: 10.1007/s11908-021-00767-w
Amber Shaye McElveen Beville, Diane Heipel, Ginger Vanhoozer, Pamela Bailey

Purpose of review: While reducing unnecessary days present of central venous catheters (CVCs) is part of central line associated bloodstream infection (CLABSI) best practices, there is limited information regarding compliance with this recommendation as well as addressing barriers to compliance.

Recent findings: Significant work has been directed towards daily audits of necessity and improving communication between members of the medical team. Other critical interventions include utilization of the electronic health record (EHR), leadership support of CLABSI reduction goals, and avoiding CVC placement over more appropriate vascular access.

Summary: Institutions have varied approaches to addressing the issue of removing idle CVCs, and more standardized approaches in checklists as well as communication, particularly on multidisciplinary rounds, will be key to CVC removal. Utilization of the EHR for reminders or appropriate documentation of necessity is a factor. Avoidance of placing a CVC or appropriateness of the CVC is also important to consider.

综述目的:虽然减少中心静脉导管(CVCs)的不必要使用天数是中心静脉相关血流感染(CLABSI)最佳实践的一部分,但关于该建议的依从性以及解决依从性障碍的信息有限。最近的调查结果:在必要性的日常审计和改善医疗小组成员之间的沟通方面开展了大量工作。其他关键干预措施包括电子健康记录(EHR)的使用、领导层对CLABSI减少目标的支持,以及避免在更合适的血管通路上放置CVC。总结:机构有不同的方法来解决清除闲置CVC的问题,在检查清单和沟通中采用更标准化的方法,特别是在多学科轮次中,将是清除CVC的关键。利用电子病历提醒或适当的必要文件是一个因素。避免设置CVC或设置CVC的适当性也是需要考虑的重要因素。
{"title":"Reducing Central Line Associated Bloodstream Infections (CLABSIs) by Reducing Central Line Days.","authors":"Amber Shaye McElveen Beville,&nbsp;Diane Heipel,&nbsp;Ginger Vanhoozer,&nbsp;Pamela Bailey","doi":"10.1007/s11908-021-00767-w","DOIUrl":"https://doi.org/10.1007/s11908-021-00767-w","url":null,"abstract":"<p><strong>Purpose of review: </strong>While reducing unnecessary days present of central venous catheters (CVCs) is part of central line associated bloodstream infection (CLABSI) best practices, there is limited information regarding compliance with this recommendation as well as addressing barriers to compliance.</p><p><strong>Recent findings: </strong>Significant work has been directed towards daily audits of necessity and improving communication between members of the medical team. Other critical interventions include utilization of the electronic health record (EHR), leadership support of CLABSI reduction goals, and avoiding CVC placement over more appropriate vascular access.</p><p><strong>Summary: </strong>Institutions have varied approaches to addressing the issue of removing idle CVCs, and more standardized approaches in checklists as well as communication, particularly on multidisciplinary rounds, will be key to CVC removal. Utilization of the EHR for reminders or appropriate documentation of necessity is a factor. Avoidance of placing a CVC or appropriateness of the CVC is also important to consider.</p>","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562022/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39596549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Therapeutic Options for Coronavirus Disease 2019 (COVID-19): Where Are We Now? 2019冠状病毒病(新冠肺炎)的治疗选择:我们现在在哪里?
IF 3.1 4区 医学 Q1 Medicine Pub Date : 2021-01-01 Epub Date: 2021-12-11 DOI: 10.1007/s11908-021-00769-8
Esther Y Golnabi, James M Sanders, Meagan L Johns, Kevin Lin, Jessica K Ortwine, Wenjing Wei, Norman S Mang, James B Cutrell

Purpose of review: Rapidly evolving treatment paradigms of coronavirus disease 2019 (COVID-19) introduce challenges for clinicians to keep up with the pace of published literature and to critically appraise the voluminous data produced. This review summarizes the clinical evidence from key studies examining the place of therapy of recommended drugs and management strategies for COVID-19.

Recent findings: The global magnitude and duration of the pandemic have resulted in a flurry of interventional treatment trials evaluating both novel and repurposed drugs targeting various aspects of the viral life cycle. Additionally, clinical observations have documented various stages or phases of COVID-19 and underscored the importance of timing for the efficacy of studied therapies. Since the start of the COVID-19 pandemic, many observational, retrospective, and randomized controlled studies have been conducted to guide management of COVID-19 using drug therapies and other management strategies. Large, randomized, or adaptive platform trials have proven the most informative to guide recommended treatments to-date. Antimicrobial stewardship programs can play a pivotal role in ensuring appropriate use of COVID-19 therapies based on evolving clinical data and limiting unnecessary antibiotics given low rates of co-infection.

Summary: Given the rapidly evolving medical literature and treatment paradigms, it is recommended to reference continuously updated, curated guidelines from national and international sources. While the drugs and management strategies mentioned in this review represent the current state of recommendations, many therapies are still under investigation to further define optimal COVID-19 treatment.

Supplementary information: The online version contains supplementary material available at 10.1007/s11908-021-00769-8.

综述目的:2019冠状病毒病(新冠肺炎)治疗模式的快速发展给临床医生带来了挑战,使他们无法跟上已发表文献的步伐,并对所产生的大量数据进行批判性评估。这篇综述总结了关键研究的临床证据,这些研究检查了推荐药物的治疗位置和COVID-19的管理策略。最近的发现:全球范围内的大流行规模和持续时间导致了一系列针对病毒生命周期各个方面的新药物和再利用药物的介入治疗试验。此外,临床观察记录了新冠肺炎的不同阶段或阶段,并强调了研究疗法疗效的时间安排的重要性。自新冠肺炎大流行开始以来,已经进行了许多观察性、回顾性和随机对照研究,以指导使用药物疗法和其他管理策略管理新冠肺炎。大型、随机或适应性平台试验已被证明是迄今为止指导推荐治疗的最具信息性的试验。抗菌药物管理计划可以在确保根据不断发展的临床数据适当使用新冠肺炎疗法方面发挥关键作用,并在共同感染率较低的情况下限制不必要的抗生素,来自国家和国际来源的精心策划的指导方针。虽然本综述中提到的药物和管理策略代表了建议的现状,但许多疗法仍在研究中,以进一步确定新冠肺炎的最佳治疗方法。补充信息:在线版本包含补充材料,可访问10.1007/s11908-021-00769-8。
{"title":"Therapeutic Options for Coronavirus Disease 2019 (COVID-19): Where Are We Now?","authors":"Esther Y Golnabi, James M Sanders, Meagan L Johns, Kevin Lin, Jessica K Ortwine, Wenjing Wei, Norman S Mang, James B Cutrell","doi":"10.1007/s11908-021-00769-8","DOIUrl":"10.1007/s11908-021-00769-8","url":null,"abstract":"<p><strong>Purpose of review: </strong>Rapidly evolving treatment paradigms of coronavirus disease 2019 (COVID-19) introduce challenges for clinicians to keep up with the pace of published literature and to critically appraise the voluminous data produced. This review summarizes the clinical evidence from key studies examining the place of therapy of recommended drugs and management strategies for COVID-19.</p><p><strong>Recent findings: </strong>The global magnitude and duration of the pandemic have resulted in a flurry of interventional treatment trials evaluating both novel and repurposed drugs targeting various aspects of the viral life cycle. Additionally, clinical observations have documented various stages or phases of COVID-19 and underscored the importance of timing for the efficacy of studied therapies. Since the start of the COVID-19 pandemic, many observational, retrospective, and randomized controlled studies have been conducted to guide management of COVID-19 using drug therapies and other management strategies. Large, randomized, or adaptive platform trials have proven the most informative to guide recommended treatments to-date. Antimicrobial stewardship programs can play a pivotal role in ensuring appropriate use of COVID-19 therapies based on evolving clinical data and limiting unnecessary antibiotics given low rates of co-infection.</p><p><strong>Summary: </strong>Given the rapidly evolving medical literature and treatment paradigms, it is recommended to reference continuously updated, curated guidelines from national and international sources. While the drugs and management strategies mentioned in this review represent the current state of recommendations, many therapies are still under investigation to further define optimal COVID-19 treatment.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s11908-021-00769-8.</p>","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665318/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39738475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evidence Regarding Rapid Initiation of Antiretroviral Therapy in Patients Living with HIV. 关于艾滋病病毒感染者快速启动抗逆转录病毒疗法的证据。
IF 3.1 4区 医学 Q1 Medicine Pub Date : 2021-01-01 Epub Date: 2021-04-02 DOI: 10.1007/s11908-021-00750-5
Sarah M Michienzi, Mario Barrios, Melissa E Badowski

Purpose of review: Rapid initiation of antiretroviral therapy (ART) is increasingly more common among clinics serving people living with human immunodeficiency virus (PLWH). It is recommended by major guidelines and is especially important in achieving the Getting to Zero (GTZ) goals by 2030. Patients should be offered the option to initiate ART as soon as possible, preferably at time of HIV diagnosis, with the goal of reducing transmission, morbidity, and mortality.

Recent findings: Three published randomized controlled trials, and several other observational, prospective, and retrospective studies, demonstrated superior rates of viral suppression (VS) with initiation of rapid ART compared to standard of care. Improved time to VS and retention in care were also observed. Based on the regimens studied, a tenofovir backbone combined with an integrase strand transfer inhibitor or protease inhibitor is recommended for rapid start initiation. Since ART is started earlier compared with standard of care, there is opportunity to achieve VS at a much faster rate, especially in the setting of starting on the day of diagnosis. What requires further evaluation is whether or not VS is sustained over time with quicker linkage and initiation of HIV care.

Summary: Initiating rapid ART in newly diagnosed PLWH provides a promising approach to achieving GTZ. When offered rapid ART, virologic suppression is improved compared to standard of care, which may reduce transmission and, ultimately, new HIV infections.

审查目的:在为人类免疫缺陷病毒感染者(PLWH)提供服务的诊所中,快速启动抗逆转录病毒疗法(ART)越来越普遍。主要指南都推荐快速启动抗逆转录病毒疗法,这对于在 2030 年前实现 "零感染"(GTZ)目标尤为重要。应让患者选择尽快开始抗逆转录病毒疗法,最好是在确诊艾滋病毒时就开始,目的是减少传播、发病率和死亡率:最近的研究结果:已发表的三项随机对照试验以及其他一些观察性、前瞻性和回顾性研究表明,与标准护理相比,开始快速抗逆转录病毒疗法的病毒抑制率(VS)更高。此外,还观察到达到病毒抑制(VS)的时间更短,治疗效果更好。根据所研究的方案,建议在快速启动抗逆转录病毒疗法时使用替诺福韦骨干药物联合整合酶链转移抑制剂或蛋白酶抑制剂。由于抗逆转录病毒疗法与标准治疗相比启动时间更早,因此有机会以更快的速度实现 VS,尤其是在诊断当天就开始治疗的情况下。小结:对新确诊的 PLWH 启动快速抗逆转录病毒疗法为实现 GTZ 提供了一种很有前景的方法。与标准护理相比,在提供快速抗逆转录病毒疗法时,病毒学抑制得到改善,这可能会减少传播,并最终减少新的 HIV 感染。
{"title":"Evidence Regarding Rapid Initiation of Antiretroviral Therapy in Patients Living with HIV.","authors":"Sarah M Michienzi, Mario Barrios, Melissa E Badowski","doi":"10.1007/s11908-021-00750-5","DOIUrl":"10.1007/s11908-021-00750-5","url":null,"abstract":"<p><strong>Purpose of review: </strong>Rapid initiation of antiretroviral therapy (ART) is increasingly more common among clinics serving people living with human immunodeficiency virus (PLWH). It is recommended by major guidelines and is especially important in achieving the Getting to Zero (GTZ) goals by 2030. Patients should be offered the option to initiate ART as soon as possible, preferably at time of HIV diagnosis, with the goal of reducing transmission, morbidity, and mortality.</p><p><strong>Recent findings: </strong>Three published randomized controlled trials, and several other observational, prospective, and retrospective studies, demonstrated superior rates of viral suppression (VS) with initiation of rapid ART compared to standard of care. Improved time to VS and retention in care were also observed. Based on the regimens studied, a tenofovir backbone combined with an integrase strand transfer inhibitor or protease inhibitor is recommended for rapid start initiation. Since ART is started earlier compared with standard of care, there is opportunity to achieve VS at a much faster rate, especially in the setting of starting on the day of diagnosis. What requires further evaluation is whether or not VS is sustained over time with quicker linkage and initiation of HIV care.</p><p><strong>Summary: </strong>Initiating rapid ART in newly diagnosed PLWH provides a promising approach to achieving GTZ. When offered rapid ART, virologic suppression is improved compared to standard of care, which may reduce transmission and, ultimately, new HIV infections.</p>","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016613/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25565714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Host Diagnostic Biomarkers of Infection in the ICU: Where Are We and Where Are We Going? ICU感染的宿主诊断生物标志物:我们在哪里,我们要去哪里?
IF 3.1 4区 医学 Q1 Medicine Pub Date : 2021-01-01 Epub Date: 2021-02-12 DOI: 10.1007/s11908-021-00747-0
Aaron J Heffernan, Kerina J Denny

Purpose of review: Early identification of infection in the critically ill patient and initiation of appropriate treatment is key to reducing morbidity and mortality. On the other hand, the indiscriminate use of antimicrobials leads to harms, many of which may be exaggerated in the critically ill population. The current method of diagnosing infection in the intensive care unit relies heavily on clinical gestalt; however, this approach is plagued by biases. Therefore, a reliable, independent biomarker holds promise in the accurate determination of infection. We discuss currently used host biomarkers used in the intensive care unit and review new and emerging approaches to biomarker discovery.

Recent findings: White cell count (including total white cell count, left shift, and the neutrophil-leucocyte ratio), C-reactive protein, and procalcitonin are the most common host diagnostic biomarkers for sepsis used in current clinical practice. However, their utility in the initial diagnosis of infection, and their role in the subsequent decision to commence treatment, remains limited. Novel approaches to biomarker discovery that are currently being investigated include combination biomarkers, host 'sepsis signatures' based on differential gene expression, site-specific biomarkers, biomechanical assays, and incorporation of new and pre-existing host biomarkers into machine learning algorithms.

Summary: To date, no single reliable independent biomarker of infection exists. Whilst new approaches to biomarker discovery hold promise, their clinical utility may be limited if previous mistakes that have afflicted sepsis biomarker research continue to be repeated.

综述目的:早期发现危重患者感染并开始适当治疗是降低发病率和死亡率的关键。另一方面,滥用抗微生物药物会造成危害,其中许多危害在重症人群中可能被夸大。目前在重症监护病房诊断感染的方法严重依赖于临床完形;然而,这种方法受到偏见的困扰。因此,一种可靠的、独立的生物标志物有望准确地确定感染。我们讨论了目前在重症监护病房使用的宿主生物标志物,并回顾了生物标志物发现的新方法。最近发现:白细胞计数(包括总白细胞计数、左移和中性粒细胞-白细胞比率)、c反应蛋白和降钙素原是目前临床实践中最常用的败血症宿主诊断生物标志物。然而,它们在感染的初步诊断中的效用以及在随后决定开始治疗中的作用仍然有限。目前正在研究的生物标志物发现的新方法包括组合生物标志物、基于差异基因表达的宿主败血症特征、位点特异性生物标志物、生物力学分析,以及将新的和已有的宿主生物标志物纳入机器学习算法。摘要:迄今为止,尚不存在单一可靠的独立感染生物标志物。虽然生物标志物发现的新方法有希望,但如果先前影响败血症生物标志物研究的错误继续重复,它们的临床应用可能会受到限制。
{"title":"Host Diagnostic Biomarkers of Infection in the ICU: Where Are We and Where Are We Going?","authors":"Aaron J Heffernan,&nbsp;Kerina J Denny","doi":"10.1007/s11908-021-00747-0","DOIUrl":"https://doi.org/10.1007/s11908-021-00747-0","url":null,"abstract":"<p><strong>Purpose of review: </strong>Early identification of infection in the critically ill patient and initiation of appropriate treatment is key to reducing morbidity and mortality. On the other hand, the indiscriminate use of antimicrobials leads to harms, many of which may be exaggerated in the critically ill population. The current method of diagnosing infection in the intensive care unit relies heavily on clinical gestalt; however, this approach is plagued by biases. Therefore, a reliable, independent biomarker holds promise in the accurate determination of infection. We discuss currently used host biomarkers used in the intensive care unit and review new and emerging approaches to biomarker discovery.</p><p><strong>Recent findings: </strong>White cell count (including total white cell count, left shift, and the neutrophil-leucocyte ratio), C-reactive protein, and procalcitonin are the most common host diagnostic biomarkers for sepsis used in current clinical practice. However, their utility in the initial diagnosis of infection, and their role in the subsequent decision to commence treatment, remains limited. Novel approaches to biomarker discovery that are currently being investigated include combination biomarkers, host 'sepsis signatures' based on differential gene expression, site-specific biomarkers, biomechanical assays, and incorporation of new and pre-existing host biomarkers into machine learning algorithms.</p><p><strong>Summary: </strong>To date, no single reliable independent biomarker of infection exists. Whilst new approaches to biomarker discovery hold promise, their clinical utility may be limited if previous mistakes that have afflicted sepsis biomarker research continue to be repeated.</p>","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11908-021-00747-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25395062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 24
Pediatric Infectious Diseases Encountered During Wartime-Part 1: Experiences and Lessons Learned From Armed Conflict in the Modern Era. 战时遇到的小儿传染病--第一部分:现代武装冲突的经验和教训。
IF 3.1 4区 医学 Q2 INFECTIOUS DISEASES Pub Date : 2021-01-01 Epub Date: 2021-12-09 DOI: 10.1007/s11908-021-00770-1
Martin Ottolini, Blake Cirks, Kathleen B Madden, Michael Rajnik

Purpose of review: Armed conflicts occur globally, with some regions experiencing heightened instability for many years. A better understanding of the infectious disease impact on children in armed conflict will allow aid organizations to anticipate and mitigate the most serious problems.

Recent findings: Armed conflicts are estimated to have caused approximately 30 million civilian deaths during the past 27 years, with two-thirds occurring in women and children. Children are extremely vulnerable to the mass population displacements, experiencing a combined loss of safety, nutrition, shelter, hygiene, and health care. Under these circumstances, the emergence and prevalence of multiple infectious diseases can result in heightened morbidity and mortality long after active conflict ceases.

Summary: Factors leading to increased infectious diseases in populations in crisis due to armed conflict and lessons learned from recent outbreaks are discussed in detail. Acute respiratory infections, diphtheria, measles, varicella, and cholera are a few of the more common infectious diseases that take advantage of populations displaced or disrupted by conflict. Key issues include the ability of countries or non-governmental organizations (NGOs) to keep up with basic childhood immunizations, and how rapidly disease outbreaks are recognized and addressed with disease-specific interventions.

审查的目的:武装冲突在全球范围内时有发生,一些地区多年来一直处于高度不稳定状态。更好地了解武装冲突中传染病对儿童的影响将使援助组织能够预测和缓解最严重的问题:据估计,在过去的 27 年中,武装冲突已造成约 3000 万平民死亡,其中三分之二是妇女和儿童。儿童极易受到大规模人口流离失所的影响,他们在安全、营养、住所、卫生和医疗保健等方面的损失加在一起。在这种情况下,多种传染病的出现和流行会在冲突结束后很长时间内导致发病率和死亡率上升:详细讨论了导致因武装冲突而陷入危机的人口中传染病增加的因素,以及从最近爆发的传染病中吸取的经验教训。急性呼吸道传染病、白喉、麻疹、水痘和霍乱是利用因冲突而流离失所或受到干扰的人口的几种较为常见的传染病。关键问题包括国家或非政府组织(NGOs)是否有能力跟上基本的儿童免疫接种,以及如何迅速识别疾病爆发并采取针对疾病的干预措施。
{"title":"Pediatric Infectious Diseases Encountered During Wartime-Part 1: Experiences and Lessons Learned From Armed Conflict in the Modern Era.","authors":"Martin Ottolini, Blake Cirks, Kathleen B Madden, Michael Rajnik","doi":"10.1007/s11908-021-00770-1","DOIUrl":"10.1007/s11908-021-00770-1","url":null,"abstract":"<p><strong>Purpose of review: </strong>Armed conflicts occur globally, with some regions experiencing heightened instability for many years. A better understanding of the infectious disease impact on children in armed conflict will allow aid organizations to anticipate and mitigate the most serious problems.</p><p><strong>Recent findings: </strong>Armed conflicts are estimated to have caused approximately 30 million civilian deaths during the past 27 years, with two-thirds occurring in women and children. Children are extremely vulnerable to the mass population displacements, experiencing a combined loss of safety, nutrition, shelter, hygiene, and health care. Under these circumstances, the emergence and prevalence of multiple infectious diseases can result in heightened morbidity and mortality long after active conflict ceases.</p><p><strong>Summary: </strong>Factors leading to increased infectious diseases in populations in crisis due to armed conflict and lessons learned from recent outbreaks are discussed in detail. Acute respiratory infections, diphtheria, measles, varicella, and cholera are a few of the more common infectious diseases that take advantage of populations displaced or disrupted by conflict. Key issues include the ability of countries or non-governmental organizations (NGOs) to keep up with basic childhood immunizations, and how rapidly disease outbreaks are recognized and addressed with disease-specific interventions.</p>","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39585268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Syndromic Multiplex Polymerase Chain Reaction (mPCR) Testing and Antimicrobial Stewardship: Current Practice and Future Directions. 综合多重聚合酶链反应(mPCR)检测与抗菌药物管理:当前实践与未来方向》。
IF 3.1 4区 医学 Q1 Medicine Pub Date : 2021-01-01 Epub Date: 2021-02-26 DOI: 10.1007/s11908-021-00748-z
Theodore S Rader, Michael P Stevens, Gonzalo Bearman

Purpose of review: Syndromic multiplex polymerase chain reaction (mPCR) panels offer the antimicrobial steward a rapid tool for optimizing and de-escalating antimicrobials. In this review, we analyze the role of syndromic mPCR in respiratory, gastrointestinal, and central nervous system infections within the context of antimicrobial stewardship efforts.

Recent findings: For all mPCR syndromic panels, multiple studies analyzed the pre-and-post implementation impact of mPCR on antimicrobial utilization. Prospective studies and trials of respiratory mPCR stewardship interventions, including diagnostic algorithms, educational efforts, co-testing with procalcitonin, and targeted provider feedback currently exist. For gastrointestinal and cerebrospinal fluid mPCR, fewer peer-reviewed reports exist for the use of mPCR in antimicrobial stewardship. These studies demonstrated an inconsistent trend towards decreasing antibiotic use with mPCR. This is further limited by a lack of statistical significance, the absence of controlled, prospective trials, and issues with data generalizability.

Summary: Antibiotic overuse may improve when mPCR is coupled with electronic medical record algorithm-based approaches and direct provider feedback by an antimicrobial stewardship professional. mPCR may prove a useful tool for antimicrobial stewardship but future studies are needed to define the best practice for its utilization.

审查目的:综合多重聚合酶链反应(mPCR)检测板为抗菌药物管理者提供了优化和降级抗菌药物的快速工具。在本综述中,我们结合抗菌药物监管工作分析了综合多重聚合酶链反应在呼吸道、胃肠道和中枢神经系统感染中的作用:对于所有 mPCR 症状分类,多项研究分析了 mPCR 实施前后对抗菌药物使用的影响。目前已有关于呼吸道 mPCR 管理干预措施的前瞻性研究和试验,包括诊断算法、教育工作、与降钙素联合检测以及有针对性的提供者反馈。就胃肠道和脑脊液 mPCR 而言,关于在抗菌药物管理中使用 mPCR 的同行评审报告较少。这些研究表明,使用 mPCR 减少抗生素使用的趋势并不一致。总结:当 mPCR 与基于电子病历算法的方法和抗菌药物管理专业人员对提供者的直接反馈相结合时,抗生素的过度使用可能会得到改善。mPCR 可能会被证明是抗菌药物管理的有用工具,但还需要未来的研究来确定其最佳使用方法。
{"title":"Syndromic Multiplex Polymerase Chain Reaction (mPCR) Testing and Antimicrobial Stewardship: Current Practice and Future Directions.","authors":"Theodore S Rader, Michael P Stevens, Gonzalo Bearman","doi":"10.1007/s11908-021-00748-z","DOIUrl":"10.1007/s11908-021-00748-z","url":null,"abstract":"<p><strong>Purpose of review: </strong>Syndromic multiplex polymerase chain reaction (mPCR) panels offer the antimicrobial steward a rapid tool for optimizing and de-escalating antimicrobials. In this review, we analyze the role of syndromic mPCR in respiratory, gastrointestinal, and central nervous system infections within the context of antimicrobial stewardship efforts.</p><p><strong>Recent findings: </strong>For all mPCR syndromic panels, multiple studies analyzed the pre-and-post implementation impact of mPCR on antimicrobial utilization. Prospective studies and trials of respiratory mPCR stewardship interventions, including diagnostic algorithms, educational efforts, co-testing with procalcitonin, and targeted provider feedback currently exist. For gastrointestinal and cerebrospinal fluid mPCR, fewer peer-reviewed reports exist for the use of mPCR in antimicrobial stewardship. These studies demonstrated an inconsistent trend towards decreasing antibiotic use with mPCR. This is further limited by a lack of statistical significance, the absence of controlled, prospective trials, and issues with data generalizability.</p><p><strong>Summary: </strong>Antibiotic overuse may improve when mPCR is coupled with electronic medical record algorithm-based approaches and direct provider feedback by an antimicrobial stewardship professional. mPCR may prove a useful tool for antimicrobial stewardship but future studies are needed to define the best practice for its utilization.</p>","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7909367/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25444347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current Infectious Disease Reports
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1